

Clinical trials of ketanserine

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
ketanserine vs placebo			
Thulesius , 1987 n=79/86 follow-up: 6 months	Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
Walden , 1991 n=17/18 follow-up: 15 months	Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
PACK , 1996 n=1930/1969 follow-up: 1 y	Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite versus Placebo	patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot	Parallel groups double blind

More details and results :

- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>

References

Thulesius, 1987:

Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. Thulesius O, Lundvall J, Kroese A, Stranden E, Hallbook T, Brunen L, Gjores JE, Akesson H, Einarsson E, Ohlin P, et al J Cardiovasc Pharmacol 1987 Jun;9:728-33 [2442541]

Walden, 1991:

Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication. Walden R, Bass A, Rabi I, Adar R J Cardiovasc Surg (Torino) 1991 Nov-Dec;32:737-40 [1752890]

PACK, 1996:

The PACK trial: morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications. Verstraete M Vasc Med 1996;1:135-40 [9546928]

Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. BMJ 1989 Feb 18;298:424-30 [2495049]

2 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
ketanserine vs placebo			
Thulesius , 1987 n=79/86 follow-up: 6 months	Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
Walden , 1991 n=17/18 follow-up: 15 months	Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite versus Placebo	patients with intermittent claudication (stade II)	Parallel groups double blind
PACK , 1996 n=1930/1969 follow-up: 1 y	Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite versus Placebo	patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot	Parallel groups double blind

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>

References

Thulesius, 1987:

Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. Thulesius O, Lundvall J, Kroese A, Strandén E, Hallbook T, Brunès L, Gjores JE, Akesson H, Einarsson E, Ohlin P, et al J Cardiovasc Pharmacol 1987 Jun;9:728-33 [2442541]

Walden, 1991:

Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication. Walden R, Bass A, Rabi I, Adar R J Cardiovasc Surg (Torino) 1991 Nov-Dec;32:737-40 [1752890]

PACK, 1996:

The PACK trial: morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications. Verstraete M Vasc Med 1996;1:135-40 [9546928]

Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. BMJ 1989 Feb 18;298:424-30 [2495049]